Monopar Therapeutics is a clinical-stage biopharmaceutical company building a pipeline around radiopharmaceuticals and other specialty drugs for serious disease. Its MNPR-101 programs target the uPAR pathway on advanced solid tumors, pairing diagnostic imaging agents with therapeutic isotopes such as lutetium and actinium. The company also advances late-stage assets outside pure oncology, including work related to Wilson disease, aiming to address conditions with limited treatment options.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -2.6 | — |
| Q2 2025 | 0 | — | -2.5 | — |
| Q3 2025 | 0 | — | -3.4 | — |
| Q4 2025 | 0 | — | -5.2 | — |
| Q1 2026 | 0 | — | -3.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Satellogic Inc. (SATL), Washington Trust Bancorp, Inc. (WASH), Alpha and Omega Semiconductor Limited (AOSL), AdaptHealth Corp. (AHCO), Lotus Technology Inc. (LOT), Churchill Capital Corp XI (CCXI)